Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q1 FY23 Earnings Presentation
30 slides from Gufic Biosciences's earnings presentation, Aug 11, 2022
Slide 1: Gufic Biosciences cover letter to exchanges
GUFIC BIOSCIENCES LIMITED CIN No. L24100MH1984PLC033519 114/LG/SE/AUG/2022/G BSL August 11, 2022 1 To, To, The Manager (CRD), The Manager, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai - 400 001 Bandr
Slide 2: Delivering Care & Cure - Investor Presentation August 2022
Delivering Care & Cure Investor Presentation August 2022
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions . This presentation does not constitute or form part of any offer or invitation
Slide 4: Q1 FY23 Business & Financial Highlights
Q1 FY23 Business & Financial Highlights
Slide 5: Q1 FY23 Business Highlights
Q1 FY23 Business Highlights Critical Care Division Domestic Business Breakup • Retained leadership position in Anti fungals & Anti bacterials • Launch of Dual Chamber Bag initially targeting Anti-infectives. Addressable market size is ~Rs. Critical Care Division 3,000 crores Infertility Division Oth
Slide 6: Q1 FY23 Business Highlights
Q1 FY23 Business Highlights Healthcare & Spark Division • We are market leaders in anti-inflammatory and herbal medicines • We initiated trial of a new product made from an Indian gum by a standardized extraction process for use in the management of asthma • Our brand Sallaki continues to be the mar
Slide 7: Q1 FY23 Business Highlights
Q1 FY23 Business Highlights Center of Excellence in Mumbai • The center of excellence will treat the skin (not just facial skin) and the body as a holistic organism using most advanced equipment, toxins and fillers for face and body contouring. • Through the center of excellence, we intend to take t
Slide 8: Innovation at Gufic
Innovation at Gufic Update on Research & Development and Innovation • The API Research Development at Navsari has made noteworthy progress in development of molecules in therapeutic categories such as Antifungal, Anticoagulant, Tetracycline Antibiotics, Progestin, Beta 3 adrenegic agonists, Antidiab
Slide 9: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 10: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q1 FY23 Q4 FY22 Q1 FY22* To ta l Rev e n u e 165.7 162.2 252.0 E B I T DA 33.6 31.6 46.9 E B I T DA M a r g i n % 20.3% 19.5% 18.7% P ro f i t b efo re Ta x 28.3 26.2 41.5 P BT M a r g i n s % 17.1% 16.1% 16.6% Ta x 7.2 5.9 10.3 P r o
Slide 11: Company Overview
Company Overview
Slide 12: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 13: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 14: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Civil Construction and Site Development work is Facility Carbapenems (Lyophilized / Dry progressing as per schedule and is near comple
Slide 15: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 16: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 17: Expanding Credibility in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 18: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 19: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 20: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 21: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 22: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 23: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 24: Historical Financials
Historical Financials
Slide 25: Historical Financials
Historical Financials Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin 12.7% 13.1% 13.8% 17.2% 19.1% 5.4% 6.3% 6.0% 9.1% 12.3% 779 149 96 488 379 351 84 306 44 52 46 39 22 23 16 2018 2019 2020 2021 FY22 2018 2019 2020 2021 FY22 2018 2019 2020 2021 FY22 CAGR 26% CAGR 40% CAGR 55% In
Slide 26: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY22 FY21 FY20 FY19 FY18 Revenue from Operations 779.2 487.7 378.8 350.8 305.6 EBITDA 148.8 83.9 52.1 46.0 38.8 EBITDA Margin % 19.1% 17.2% 13.8% 13.1% 12.7% Profit before Tax 126.8 57.7 30.1 35.3 30.0 PBT Margin % 16.3% 11.8% 7.9% 10.1% 9.8% Tax 31.0 13.
Slide 27: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 9.7 9.7 9.7 7.8 7.8 Other Equity 259.4 163.7 119.6 67.6 46.4 Total Equity 269.1 173.4 129.3 75.3 54.1 Non-Current Liabilities Financial Liabilities i. Borrowings 47
Slide 28: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Non-Current Assets Property, plant and equipment 111.8 93.8 72.7 24.1 22.4 Intangible assets 0.6 0.4 0.6 0.4 0.5 Capital work-in-progress 40.9 13.4 30.6 9.6 2.1 Right of use assets 2.8 5.8 9.3 0.0 0.0 Financial As
Slide 29: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) Mar-22 FY21 FY20 FY19 FY18 Net Profit Before Tax 95.8 44.2 22.7 21.9 16.5 Adjustments for: Non - Cash Items / Other Investment or Financial Items 51.9 44.3 32.1 26.8 25.6 Operating profit before working capital changes 147.7 88.5 54.8 48.7 42.0 Ch
Slide 30: Thank You
THANK YOU Company: Gufic Biosciences Limited Investor Relations Advisors: Strategic Growth Advisors (SGA) CIN: L24100MH1984PLC033519 CIN: U74140MH2010PTC204285 Mr. Avik Das – Investor Relations Mr. Deven Dhruva / Mr. Jigar Kavaiya avik.das@guficbio.com deven.dhruva@sgapl.net / jigar.kavaiya@sgapl.ne